Enviar búsqueda
Cargar
7 efecto de introducción de vacuna conjugada neumocócica sobre el sp resistente
•
0 recomendaciones
•
352 vistas
Ruth Vargas Gonzales
Seguir
Salud y medicina
Educación
Denunciar
Compartir
Denunciar
Compartir
1 de 10
Descargar ahora
Descargar para leer sin conexión
Recomendados
nurmakhanovetalCCHFjul2015
nurmakhanovetalCCHFjul2015
kenny yeh
Idsa neutropenia febril
Idsa neutropenia febril
jeslyHaelDoriaAtenci
Microba journal 1
Microba journal 1
KAHAR KAHAR
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
John Blue
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
Valentina Corona
Poster 16th eccmid p596 1 hiv hbv vaccination 2006
Poster 16th eccmid p596 1 hiv hbv vaccination 2006
Michel Rotily
Zika Virus: Medical Countermeasure Development Challenges by Robert W. Malone
Zika Virus: Medical Countermeasure Development Challenges by Robert W. Malone
Jan-Cedric Hansen
Guideline useofantimicrobialagentsinneutropenicpatients
Guideline useofantimicrobialagentsinneutropenicpatients
negrulo2013
Recomendados
nurmakhanovetalCCHFjul2015
nurmakhanovetalCCHFjul2015
kenny yeh
Idsa neutropenia febril
Idsa neutropenia febril
jeslyHaelDoriaAtenci
Microba journal 1
Microba journal 1
KAHAR KAHAR
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
John Blue
Covid-19: state of art at 30.03.2020
Covid-19: state of art at 30.03.2020
Valentina Corona
Poster 16th eccmid p596 1 hiv hbv vaccination 2006
Poster 16th eccmid p596 1 hiv hbv vaccination 2006
Michel Rotily
Zika Virus: Medical Countermeasure Development Challenges by Robert W. Malone
Zika Virus: Medical Countermeasure Development Challenges by Robert W. Malone
Jan-Cedric Hansen
Guideline useofantimicrobialagentsinneutropenicpatients
Guideline useofantimicrobialagentsinneutropenicpatients
negrulo2013
Epidemiology of Covid-19
Epidemiology of Covid-19
Valentina Corona
Caring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 era
Valentina Corona
Between Scylla Charybdis
Between Scylla Charybdis
Valentina Corona
Vancomyocin Resistant Staph Aerus
Vancomyocin Resistant Staph Aerus
Michael Rangel
BCMJ_52Vol6_tularemia
BCMJ_52Vol6_tularemia
Ross George Berringer
Ebola Truth
Ebola Truth
John Bergman
Editorial frontiers ov
Editorial frontiers ov
Eliyahu Schuman
The Vaccine Death Report
The Vaccine Death Report
Guy Boulianne
Expert evidence-pfizer-children
Expert evidence-pfizer-children
LesBennett1
Dear vaccinator-notice-of-potential-liability
Dear vaccinator-notice-of-potential-liability
LesBennett1
Vaccine death-report
Vaccine death-report
LesBennett1
Vaccine Truth
Vaccine Truth
John Bergman
5.rivas vivent etal 2006 (1)
5.rivas vivent etal 2006 (1)
Nicole Rivera
Aspergillosis 2008 guideline
Aspergillosis 2008 guideline
Loveis1able Khumpuangdee
Immunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 Infection
Rongpong Plongla
Efficacité de l'hydroxychloroquine et de l'azithromycine
Efficacité de l'hydroxychloroquine et de l'azithromycine
Société Tripalio
Vaccination and-autoimmunity
Vaccination and-autoimmunity
Marly0710
Vacunas vhp 2012
Vacunas vhp 2012
IMSS
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
RodolfoGamarra
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
IPN
Influenza
Influenza
Luis Rangel
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Christian Wilhelm
Más contenido relacionado
La actualidad más candente
Epidemiology of Covid-19
Epidemiology of Covid-19
Valentina Corona
Caring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 era
Valentina Corona
Between Scylla Charybdis
Between Scylla Charybdis
Valentina Corona
Vancomyocin Resistant Staph Aerus
Vancomyocin Resistant Staph Aerus
Michael Rangel
BCMJ_52Vol6_tularemia
BCMJ_52Vol6_tularemia
Ross George Berringer
Ebola Truth
Ebola Truth
John Bergman
Editorial frontiers ov
Editorial frontiers ov
Eliyahu Schuman
The Vaccine Death Report
The Vaccine Death Report
Guy Boulianne
Expert evidence-pfizer-children
Expert evidence-pfizer-children
LesBennett1
Dear vaccinator-notice-of-potential-liability
Dear vaccinator-notice-of-potential-liability
LesBennett1
Vaccine death-report
Vaccine death-report
LesBennett1
Vaccine Truth
Vaccine Truth
John Bergman
5.rivas vivent etal 2006 (1)
5.rivas vivent etal 2006 (1)
Nicole Rivera
Aspergillosis 2008 guideline
Aspergillosis 2008 guideline
Loveis1able Khumpuangdee
Immunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 Infection
Rongpong Plongla
Efficacité de l'hydroxychloroquine et de l'azithromycine
Efficacité de l'hydroxychloroquine et de l'azithromycine
Société Tripalio
Vaccination and-autoimmunity
Vaccination and-autoimmunity
Marly0710
Vacunas vhp 2012
Vacunas vhp 2012
IMSS
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
RodolfoGamarra
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
IPN
La actualidad más candente
(20)
Epidemiology of Covid-19
Epidemiology of Covid-19
Caring for patients with cancer in the COVID-19 era
Caring for patients with cancer in the COVID-19 era
Between Scylla Charybdis
Between Scylla Charybdis
Vancomyocin Resistant Staph Aerus
Vancomyocin Resistant Staph Aerus
BCMJ_52Vol6_tularemia
BCMJ_52Vol6_tularemia
Ebola Truth
Ebola Truth
Editorial frontiers ov
Editorial frontiers ov
The Vaccine Death Report
The Vaccine Death Report
Expert evidence-pfizer-children
Expert evidence-pfizer-children
Dear vaccinator-notice-of-potential-liability
Dear vaccinator-notice-of-potential-liability
Vaccine death-report
Vaccine death-report
Vaccine Truth
Vaccine Truth
5.rivas vivent etal 2006 (1)
5.rivas vivent etal 2006 (1)
Aspergillosis 2008 guideline
Aspergillosis 2008 guideline
Immunology and Detection of Acute HIV-1 Infection
Immunology and Detection of Acute HIV-1 Infection
Efficacité de l'hydroxychloroquine et de l'azithromycine
Efficacité de l'hydroxychloroquine et de l'azithromycine
Vaccination and-autoimmunity
Vaccination and-autoimmunity
Vacunas vhp 2012
Vacunas vhp 2012
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteri...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
West Nile Virus and Other Domestic Nationally Notifiable Arboviral Diseases —...
Similar a 7 efecto de introducción de vacuna conjugada neumocócica sobre el sp resistente
Influenza
Influenza
Luis Rangel
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Christian Wilhelm
7. hcv in mexico
7. hcv in mexico
Erwin Chiquete, MD, PhD
BMJ Open-2016-Conway Morris--2
BMJ Open-2016-Conway Morris--2
Tracey Mare
Influenza a h1 ni latest
Influenza a h1 ni latest
Bea Galang
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter...
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter...
CrimsonpublishersCJMI
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002–2006
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002–2006
gu88w9
articulo de divulgación científica: a large outbreak of histoplasmosis acapul...
articulo de divulgación científica: a large outbreak of histoplasmosis acapul...
IPN
RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)
J.A. Zamora-Legoff
1 s2.0-s2352396419302592-main (1)
1 s2.0-s2352396419302592-main (1)
Miguel Alca Alvaro
Critical Care Endotypes
Critical Care Endotypes
David Maslove
12 café aula 01 - dr. vicente vaz - novagripe
12 café aula 01 - dr. vicente vaz - novagripe
itgfiles
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
John Blue
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
iosrphr_editor
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
iosrphr_editor
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...
asclepiuspdfs
Epidemiology of wound_infection_in_a_surgical_ward_of_a_tertiary_care_hospita...
Epidemiology of wound_infection_in_a_surgical_ward_of_a_tertiary_care_hospita...
Jacob Amofa
Respiratory epidemic impact on workers health
Respiratory epidemic impact on workers health
laura emilce flores rodriguez
Antibiotics bugs- us1
Antibiotics bugs- us1
Reham Ragab
Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]
khaledalazzazy1
Similar a 7 efecto de introducción de vacuna conjugada neumocócica sobre el sp resistente
(20)
Influenza
Influenza
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
7. hcv in mexico
7. hcv in mexico
BMJ Open-2016-Conway Morris--2
BMJ Open-2016-Conway Morris--2
Influenza a h1 ni latest
Influenza a h1 ni latest
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter...
Characterization of Mycobacterium Tuberculosis Complex Strains: A Multicenter...
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002–2006
Vancomycin-Resistant Staphylococcus aureus in the United States, 2002–2006
articulo de divulgación científica: a large outbreak of histoplasmosis acapul...
articulo de divulgación científica: a large outbreak of histoplasmosis acapul...
RA-ILD Infection Poster ACR 2016 (Final Version)
RA-ILD Infection Poster ACR 2016 (Final Version)
1 s2.0-s2352396419302592-main (1)
1 s2.0-s2352396419302592-main (1)
Critical Care Endotypes
Critical Care Endotypes
12 café aula 01 - dr. vicente vaz - novagripe
12 café aula 01 - dr. vicente vaz - novagripe
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
Dr. Kurt Stevenson - Antimicrobial Resistance Surveillance and Management in ...
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
Common antibiotics prescribed for acute respiratory tract infected children i...
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...
People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Prese...
Epidemiology of wound_infection_in_a_surgical_ward_of_a_tertiary_care_hospita...
Epidemiology of wound_infection_in_a_surgical_ward_of_a_tertiary_care_hospita...
Respiratory epidemic impact on workers health
Respiratory epidemic impact on workers health
Antibiotics bugs- us1
Antibiotics bugs- us1
Antibiotics bugs- us1 [autosaved]
Antibiotics bugs- us1 [autosaved]
Más de Ruth Vargas Gonzales
Fidias g. arias_el_proyecto_de_investigacion_5ta._edicion-
Fidias g. arias_el_proyecto_de_investigacion_5ta._edicion-
Ruth Vargas Gonzales
Introducción a la Investigación cualitativa
Introducción a la Investigación cualitativa
Ruth Vargas Gonzales
Metodología de la investigación módulo 1
Metodología de la investigación módulo 1
Ruth Vargas Gonzales
Metodología de la investigación manual para el desarrollo de personal de salud
Metodología de la investigación manual para el desarrollo de personal de salud
Ruth Vargas Gonzales
Alfabeto dactilologico
Alfabeto dactilologico
Ruth Vargas Gonzales
Alfredo guzman-el-drama-de-la-muerte-materna-en-el-peru.-casos-emblematicos
Alfredo guzman-el-drama-de-la-muerte-materna-en-el-peru.-casos-emblematicos
Ruth Vargas Gonzales
Directiva manejo de its sintomaticas en gentantes y mujeres lactantes
Directiva manejo de its sintomaticas en gentantes y mujeres lactantes
Ruth Vargas Gonzales
minsa-propuesta-nt-atencion-integral-salud-materna
minsa-propuesta-nt-atencion-integral-salud-materna
Ruth Vargas Gonzales
Planes de beneficios_en_salud_de_america_latina
Planes de beneficios_en_salud_de_america_latina
Ruth Vargas Gonzales
Encuesta de satisfacción_de_usuarios_2011
Encuesta de satisfacción_de_usuarios_2011
Ruth Vargas Gonzales
HIS PLANIFICACION FAMILIAR
HIS PLANIFICACION FAMILIAR
Ruth Vargas Gonzales
HIS materno perinatal
HIS materno perinatal
Ruth Vargas Gonzales
HIS CANCER
HIS CANCER
Ruth Vargas Gonzales
HIS ETS
HIS ETS
Ruth Vargas Gonzales
Clase Como llenar el HIS en Materno y PPFF
Clase Como llenar el HIS en Materno y PPFF
Ruth Vargas Gonzales
Ventura seminario sst-inclusionparticipaciontrabajadoressst-2012-04-24
Ventura seminario sst-inclusionparticipaciontrabajadoressst-2012-04-24
Ruth Vargas Gonzales
Cam seminario sst-riesgosdisergonomicos-2012-04-24
Cam seminario sst-riesgosdisergonomicos-2012-04-24
Ruth Vargas Gonzales
Arestegui seminario sst-riesgospsicosociales-2012-04-24
Arestegui seminario sst-riesgospsicosociales-2012-04-24
Ruth Vargas Gonzales
Reglamento ensayos clinicos
Reglamento ensayos clinicos
Ruth Vargas Gonzales
Modelo de organizacion[22 7-11]
Modelo de organizacion[22 7-11]
Ruth Vargas Gonzales
Más de Ruth Vargas Gonzales
(20)
Fidias g. arias_el_proyecto_de_investigacion_5ta._edicion-
Fidias g. arias_el_proyecto_de_investigacion_5ta._edicion-
Introducción a la Investigación cualitativa
Introducción a la Investigación cualitativa
Metodología de la investigación módulo 1
Metodología de la investigación módulo 1
Metodología de la investigación manual para el desarrollo de personal de salud
Metodología de la investigación manual para el desarrollo de personal de salud
Alfabeto dactilologico
Alfabeto dactilologico
Alfredo guzman-el-drama-de-la-muerte-materna-en-el-peru.-casos-emblematicos
Alfredo guzman-el-drama-de-la-muerte-materna-en-el-peru.-casos-emblematicos
Directiva manejo de its sintomaticas en gentantes y mujeres lactantes
Directiva manejo de its sintomaticas en gentantes y mujeres lactantes
minsa-propuesta-nt-atencion-integral-salud-materna
minsa-propuesta-nt-atencion-integral-salud-materna
Planes de beneficios_en_salud_de_america_latina
Planes de beneficios_en_salud_de_america_latina
Encuesta de satisfacción_de_usuarios_2011
Encuesta de satisfacción_de_usuarios_2011
HIS PLANIFICACION FAMILIAR
HIS PLANIFICACION FAMILIAR
HIS materno perinatal
HIS materno perinatal
HIS CANCER
HIS CANCER
HIS ETS
HIS ETS
Clase Como llenar el HIS en Materno y PPFF
Clase Como llenar el HIS en Materno y PPFF
Ventura seminario sst-inclusionparticipaciontrabajadoressst-2012-04-24
Ventura seminario sst-inclusionparticipaciontrabajadoressst-2012-04-24
Cam seminario sst-riesgosdisergonomicos-2012-04-24
Cam seminario sst-riesgosdisergonomicos-2012-04-24
Arestegui seminario sst-riesgospsicosociales-2012-04-24
Arestegui seminario sst-riesgospsicosociales-2012-04-24
Reglamento ensayos clinicos
Reglamento ensayos clinicos
Modelo de organizacion[22 7-11]
Modelo de organizacion[22 7-11]
Último
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
narwatsonia7
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
Nehru place Escorts
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Gabriel Guevara MD
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
MedicoseAcademics
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
parulsinha
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
parulsinha
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
sonalikaur4
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
saminamagar
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
MiadAlsulami
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
narwatsonia7
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
aliya bhat
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
Miss joya
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Call Girls Jayanagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jayanagar Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Nehru place Escorts
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Miss joya
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
sonalikaur4
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
narwatsonia7
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
narwatsonia7
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
9953056974 Low Rate Call Girls In Saket, Delhi NCR
Último
(20)
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
Hemostasis Physiology and Clinical correlations by Dr Faiza.pdf
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Call Girls Service In Shyam Nagar Whatsapp 8445551418 Independent Escort Service
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
Low Rate Call Girls Mumbai Suman 9910780858 Independent Escort Service Mumbai
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Artifacts in Nuclear Medicine with Identifying and resolving artifacts.
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Book Call Girls in Kasavanahalli - 7001305949 with real photos and phone numbers
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
Ahmedabad Call Girls CG Road 🔝9907093804 Short 1500 💋 Night 6000
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
VIP Call Girls Pune Vrinda 9907093804 Short 1500 Night 6000 Best call girls S...
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Call Girls Jayanagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jayanagar Just Call 7001305949 Top Class Call Girl Service Available
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
Kolkata Call Girls Services 9907093804 @24x7 High Class Babes Here Call Now
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Mumbai Call Girls Service 9910780858 Real Russian Girls Looking Models
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hosur Just Call 7001305949 Top Class Call Girl Service Available
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
7 efecto de introducción de vacuna conjugada neumocócica sobre el sp resistente
1.
new england
The journal of medicine established in 1812 april 6, 2006 vol. 354 no. 14 Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae Moe H. Kyaw, Ph.D., M.P.H., Ruth Lynfield, M.D., William Schaffner, M.D., Allen S. Craig, M.D., James Hadler, M.D., M.P.H., Arthur Reingold, M.D., Ann R. Thomas, M.D., M.P.H., Lee H. Harrison, M.D., Nancy M. Bennett, M.D., Monica M. Farley, M.D., Richard R. Facklam, Ph.D., James H. Jorgensen, Ph.D., John Besser, M.S., Elizabeth R. Zell, M.Stat., Anne Schuchat, M.D., and Cynthia G. Whitney, M.D., M.P.H., for Active Bacterial Core Surveillance of the Emerging Infections Program Network A bs t r ac t Background Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for in- From the Respiratory Diseases Branch, fants in the United States in 2000, are responsible for most penicillin-resistant infec- Division of Bacterial and Mycotic Diseas- es, National Center for Infectious Diseases, tions. We examined the effect of this vaccine on invasive disease caused by resistant Centers for Disease Control and Preven- strains. tion, Atlanta (M.H.K., R.R.F., E.R.Z., A.S., C.G.W.); the Minnesota Department of Methods Health, Minneapolis (R.L., J.B.); Vander- We used laboratory-based data from Active Bacterial Core surveillance to measure bilt University School of Medicine (W.S.) and the Tennessee Department of Health disease caused by antibiotic-nonsusceptible pneumococci from 1996 through 2004. (A.S.C.) — both in Nashville; the Connecti- Cases of invasive disease, defined as disease caused by pneumococci isolated from cut Department of Public Health, Hart- a normally sterile site, were identified in eight surveillance areas. Isolates underwent ford (J.H.); the School of Public Health, University of California, Berkeley (A.R.); serotyping and susceptibility testing. the Emerging Infections Programs, Ore- gon Department of Human Services, Results Health Division, Portland (A.R.T.); Johns Rates of invasive disease caused by penicillin-nonsusceptible strains and strains not Hopkins University Bloomberg School of Public Health, Baltimore (L.H.H.); the susceptible to multiple antibiotics peaked in 1999 and decreased by 2004, from 6.3 Monroe County Department of Health to 2.7 cases per 100,000 (a decline of 57 percent; 95 percent confidence interval, 55 and the University of Rochester — both to 58 percent) and from 4.1 to 1.7 cases per 100,000 (a decline of 59 percent; 95 percent in Rochester, N.Y. (N.M.B.); Emory Uni- versity School of Medicine and the Veter- confidence interval, 58 to 60 percent), respectively. Among children under two years ans Affairs Medical Center — both in At- of age, disease caused by penicillin-nonsusceptible strains decreased from 70.3 to lanta (M.M.F.); and the University of Texas 13.1 cases per 100,000 (a decline of 81 percent; 95 percent confidence interval, 80 to Health Science Center, San Antonio (J.H.J.). Address reprint requests to Dr. Whitney 82 percent). Among persons 65 years of age or older, disease caused by penicillin- at CDC Mailstop C-23, 1600 Clifton Rd. NE, nonsusceptible strains decreased from 16.4 to 8.4 cases per 100,000 (a decline of Atlanta, GA 30333, or at cwhitney@cdc.gov. 49 percent). Rates of resistant disease caused by vaccine serotypes fell 87 percent. N Engl J Med 2006;354:1455-63. An increase was seen in disease caused by serotype 19A, a serotype not included in the Copyright © 2006 Massachusetts Medical Society. vaccine (from 2.0 to 8.3 per 100,000 among children under two years of age). Conclusions The rate of antibiotic-resistant invasive pneumococcal infections decreased in young children and older persons after the introduction of the conjugate vaccine. There was an increase in infections caused by serotypes not included in the vaccine. n engl j med 354;14 www.nejm.org april 6, 2006 1455 Downloaded from www.nejm.org on July 31, 2008 . Copyright © 2006 Massachusetts Medical Society. All rights reserved.
2.
The
n e w e ng l a n d j o u r na l of m e dic i n e A ntibiotic-resistant pneumococci eight surveillance areas: the Atlanta metropoli- complicate treatment decisions, cause treat- tan area (eight counties); Portland, Oregon (three ment failures, and increase the costs of counties); San Francisco County, California; Min- medical care. Worldwide, most antibiotic-resis- neapolis and St. Paul (seven counties); the Balti- tant infections are caused by five of the seven sero- more metropolitan area (six counties); the state types in the 7-valent pneumococcal conjugate of Connecticut; and parts of Tennessee (four coun- vaccine (6B, 9V, 14, 19F, and 23F).1 In 1998, 24 per- ties). Seven counties comprising the Rochester, cent of invasive pneumococcal isolates in the Unit- New York, metropolitan area were added in 1998. ed States were nonsusceptible to penicillin, and The surveillance methods for detecting cases of these five serotypes comprised 78 percent of such invasive pneumococcal disease did not change strains.2 Modeling predicted that in the absence during the study period. The population under of a pneumococcal conjugate vaccine, the propor- surveillance for this analysis ranged from 14.3 mil- tion of pneumococcal strains that were nonsus- lion to 16.9 million, including nearly 500,000 chil- ceptible to both penicillin and erythromycin could dren under two years of age. reach 41 percent by 2004.3 Because of the asso- Active Bacterial Core surveillance methods de- ciation between serotype and resistance, the con- fined a case of invasive disease as an illness in jugate vaccine would be expected to reduce the which pneumococcus was isolated from a nor- incidence of disease caused by resistant strains, mally sterile site, such as blood, cerebrospinal even though the vaccine is designed to induce fluid, or pleural fluid. Isolates underwent suscep- antibodies against certain capsular types. tibility testing by broth microdilution at the CDC, A pneumococcal conjugate vaccine was licensed the Minnesota Department of Health, or the Uni- for use in young children in the United States in versity of Texas Health Science Center at San 2000. The vaccine is recommended for all chil- Antonio. Antibiotic susceptibility was defined ac- dren under two years of age and for children two cording to break points for minimal inhibitory to four years of age who have certain chronic ill- concentrations as determined in 2004 by the nesses or other high-risk conditions.4 Data from Clinical and Laboratory Standards Institute (for- 20015 and from a single site in 20026 indicated merly the National Committee for Clinical Labo- that there had been a large decrease in invasive ratory Standards).7 Isolates with intermediate or disease, including infections caused by resistant high-level resistance were defined as nonsuscep- strains. Whether vaccine use would induce the tible. Isolates were considered nonsusceptible to emergence of serotypes that were typically not multiple antibiotics if they were nonsusceptible resistant as clinically significant causes of resis- to at least three of the following: penicillin, eryth- tant infections was unknown. In addition, the romycin, trimethoprim–sulfamethoxazole, tetra- possibility that use of a vaccine that targets only cycline, chloramphenicol, clindamycin, rifampin, 7 of 90 pneumococcal serotypes would lead to an and levofloxacin. increase in disease by nonvaccine types (so-called Serotyping was performed at the CDC or the replacement disease) was a concern. We used Minnesota Department of Health by the Quellung population-based data from Active Bacterial Core reaction. The 7-valent conjugate vaccine serotypes surveillance, part of the Emerging Infections Pro- included types 4, 6B, 9V, 14, 18C, 19F, and 23F. gram of the Centers for Disease Control and Pre- Other serotypes in these serogroups, including vention (CDC), to evaluate further the effect of 6A, 9A, 9L, 9 N, 18A, 18B, 18F, 19A, 19B, 19C, the conjugate pneumococcal vaccine on invasive 23A, and 23B, were regarded as vaccine-related. disease caused by antibiotic-resistant strains in All others were nonvaccine types. the United States. Rates of invasive pneumococcal disease, ex- pressed as the number of cases per 100,000 popu- Me thods lation, were calculated for the surveillance areas with the use of estimates from the U.S. Census Active Bacterial Core surveillance is an active, Bureau for each respective year, followed by ad- population-based system that has been described justment for race and age according to the U.S. previously (www.cdc.gov/abcs).2 We included cases population. Projected numbers of cases in the of invasive pneumococcal disease identified from United States were determined by multiplying the January 1, 1996, through December 31, 2004, in adjusted rate by the U.S. population. Estimated 1456 n engl j med 354;14 www.nejm.org april 6, 2006 Downloaded from www.nejm.org on July 31, 2008 . Copyright © 2006 Massachusetts Medical Society. All rights reserved.
3.
pneumococcal vaccine and
drug-resistant infection numbers of cases for 2004 were calculated on +208 (+164 to +259) the basis of the 2003 population. Because isolates % Change (95% CI) −100 (−93 to −100) −100 (−93 to −100) +72 (+53 to +93) −73 (−67 to −77) −73 (−69 to −76) −82 (−80 to −84) −85 (−76 to −87) −49 (−46 to −51) −79 (−78 to −81) −83 (−79 to −85) −27 (−18 to −36) +15 (+6 to +24) were not available for all cases, rates of antibiotic- nonsusceptible disease were computed by multi- Persons ≥65 Yr of Age plying the percentage of cases that were nonsus- ceptible by the total rate of disease calculated with all cases. Likewise, we calculated serotype-spe- cific rates according to the assumption that the distribution of serotypes among cases without 2004 8.4 2.6 0.4 0.8 0.8 0.1 0.4 4.0 1.2 2.2 1.9 cases/100,000 serotype data was the same as that among cases 0 0 with serotype data. Changes in the rates of anti- biotic-nonsusceptible disease were calculated for 1999 16.4 12.3 1.5 2.8 4.7 0.7 2.4 3.5 1.7 1.3 0.6 0.1 0.1 the comparison between 1999 — the year before Table 1. Incidence of Invasive Pneumococcal Disease Caused by Penicillin-Nonsusceptible Strains in 1999 and 2004, According to Serotype.* the vaccine was introduced — and 2004. Two-sided P values of less than 0.05 were considered to in- −98 (−97.6 to −98.4) −99 (−98.7 to −99.5) +313 (+247 to +393) % Change (95% CI) dicate statistical significance and were not ad- +150 (+84 to +238) −100 (−99 to −100) +25 (+13 to +39) −81 (−80 to −82) −97 (−96 to −98) −94 (−92 to −96) −65 (−56 to −72) −97 (−96 to −98) justed for multiple testing. Undefined Undefined SAS (version 9.1, SAS Institute) and StatXact * CI denotes confidence interval. Values for the serotype subgroups may not sum to the total number because of rounding. programs were used for data analysis. We used Children <2 Yr of Age multivariable logistic-regression modeling to as- sess factors associated with invasive disease caused by penicillin-nonsusceptible pneumococci in 2004. We assessed collinearity and interactions among 2004 1.2 0.2 0.3 0.2 0.5 10.2 1.4 8.3 1.9 13.1 cases/100,000 variables in the final model. 0 0 0 R e sult s 1999 70.3 61.5 8.6 6.1 30.5 8.4 7.9 8.2 4.1 2.0 0.8 0 0 All Ages We identified 28,336 cases from 1996 through 2004; isolates were available for 24,825 (87.6 per- % Change (95% CI) +238 (+214 to +263) +195 (+165 to +230) −100 (−96 to −100) +54 (+47 to +61) cent). For 96.4 percent of the cases, isolates were −57 (−55 to −58) −87 (−86 to −88) −78 (−75 to −80) −78 (−76 to −79) −92 (−92 to −79) −73 (−54 to −84) −73 (−69 to −76) −91 (−89 to −92) −22 (−15 to −28) available from blood; for 3.8 percent, from cere- brospinal fluid; for 1.5 percent, from pleural fluid; Persons of Any Age and for 1.0 percent, from other sources (for some cases, isolates were available from more than one source). All isolates were serotyped and tested for antibiotic susceptibility. 2004 0.07 0.08 Overall rates of invasive pneumococcal dis- 2.7 0.7 0.1 0.2 0.2 1.6 0.3 1.2 0.5 cases/100,000 0 0 ease ranged from 23.7 to 25.1 cases per 100,000 persons between 1996 and 1999; the number of cases per 100,000 persons decreased to 20.9 in 1999 0.03 0.02 6.3 5.0 0.6 1.1 2.0 0.5 0.8 1.0 0.4 0.3 0.2 2000, 16.9 in 2001, 14.0 in 2002, 14.0 in 2003, and 12.6 in 2004. The incidence of penicillin-nonsus- ceptible disease increased from 5.4 cases per All vaccine-related serotypes 100,000 in 1996 to a peak of 6.3 per 100,000 in All nonvaccine serotypes 1999 (P<0.04). Comparing 1999 and 2004 data, All vaccine serotypes we found that the overall rate of penicillin-non- susceptible disease decreased from 6.3 to 2.7 per All serotypes 100,000 (a decline of 57 percent; 95 percent con- Serotype fidence interval, 55 to 58 percent) (Table 1). Simi- 18C 19A 19F 23F 6A 6B 9V 14 4 lar decreases were found for erythromycin-non- susceptible disease (from 4.7 to 2.3 per 100,000, n engl j med 354;14 www.nejm.org april 6, 2006 1457 Downloaded from www.nejm.org on July 31, 2008 . Copyright © 2006 Massachusetts Medical Society. All rights reserved.
4.
The
n e w e ng l a n d j o u r na l of m e dic i n e a decline of 51 percent [95 percent confidence were no significant changes in the proportion of interval, 50 to 53 percent]) and for disease caused isolates that were nonsusceptible to cefotaxime, by strains with reduced susceptibility to mul- tetracycline, or levofloxacin. The proportion of tiple antibiotics (from 4.1 to 1.7 per 100,000, a isolates that were nonsusceptible to any tested decline of 59 percent [95 percent confidence inter- antibiotic was 37.7 percent in 1999 and 33.6 per- val, 58 to 60 percent]). Rates of penicillin-non- cent in 2004 (P = 0.002). Most individual serotypes susceptible disease due to vaccine serotypes fell were not less resistant in 2004 than in 1999 (Ta- from 5.0 to 0.7 per 100,000 (a decline of 87 per- ble 2). Among the vaccine serotypes, only sero- cent; 95 percent confidence interval, 86 to 88 type 23F was significantly less often resistant in percent) (Table 1). Rates of disease caused by 2004 than in 1999; vaccine-related serotype 19A vaccine-related strains increased by 54 percent was resistant more often. (from 1.0 to 1.6 per 100,000); this change re- flected a decrease (by 22 percent) in the rate of Rates of Disease According to Age disease due to serotype 6A and a large increase Children under Five Years of Age (by 238 percent) in the rate of disease due to sero- The rates of penicillin-nonsusceptible invasive dis- type 19A. The rate of penicillin-nonsusceptible ease among children under five years of age disease due to nonvaccine serotypes increased ranged from 25.9 to 33.8 per 100,000 between from 0.2 per 100,000 in 1999 to 0.5 per 100,000 1996 and 1999, before the introduction of the con- in 2004. jugate vaccine, and fell to 7.5 per 100,000 in 2004. The decrease in the rate of penicillin-nonsus- Rates of resistant infections were highest among ceptible disease was largest in Georgia (a decrease children under two years of age, the target age of 68 percent, from 11.1 per 100,000 in 1999 to for use of the conjugate vaccine. In this age group, 3.6 per 100,000 in 2004) and smallest in New the rate of invasive disease caused by penicillin- York (a decrease of 11 percent, from 3.3 to 2.9 per nonsusceptible pneumococci decreased by 81 per- 100,000). The rate of penicillin-nonsusceptible cent (95 percent confidence interval, 80 to 82 per- disease decreased by 65 percent (from 11.7 to 4.1 cent), from a peak of 70.3 per 100,000 in 1999 to per 100,000) in Tennessee, by 60 percent (from 13.1 per 100,000 in 2004 (Fig. 1). The rate of in- 5.5 to 2.2 per 100,000) in Minnesota, by 57 per- vasive disease due to erythromycin-nonsuscep- cent (from 3.7 to 1.6 per 100,000) in Oregon, by tible strains decreased by 80 percent (95 percent 53 percent (from 3.8 to 1.8 per 100,000) in Califor- confidence interval, 78 to 81 percent), from 58.6 nia, by 53 percent (from 5.8 to 2.7 per 100,000) in to 12.0 per 100,000, and the rate of disease due to Maryland, and by 42 percent (from 4.9 to 2.9 per strains with reduced susceptibility to both peni- 100,000) in Connecticut. The change in rate was cillin and erythromycin decreased by 83 percent significant at all sites except New York. (95 percent confidence interval, 82 to 85 percent), The proportion of isolates that were penicil- from 51.5 to 8.6 per 100,000. Among children two lin-nonsusceptible increased from 21.6 percent to four years of age, the rate of penicillin-nonsus- in 1996 to 25.8 percent in 1999 and 25.9 percent ceptible disease decreased by 60 percent (95 per- in 2000 and fell to 21.6 percent in 2004 (P<0.001 cent confidence interval, 56 to 65 percent), from for the comparison between 1999 and 2004). The 9.4 to 3.7 per 100,000 (Fig. 2). The rate of disease proportion of erythromycin-nonsusceptible iso- caused by strains nonsusceptible to multiple an- lates ranged from 10.7 percent in 1996 to 19.4 tibiotics decreased by 84 percent (95 percent con- percent in 1999 and 20.6 percent in 2000; the fidence interval, 82 to 85 percent), from 53.8 to proportion of isolates that were erythromycin- 8.8 per 100,000, among children under two years nonsusceptible did not change significantly af- of age, and by 64 percent (95 percent confidence ter the introduction of the vaccine and was 18.1 interval, 58 to 68 percent), from 6.2 to 2.3 per percent in 2004 (P = 0.23 for the comparison with 100,000, among children two to four years of age. 1999 rates). When data from 1999 and 2004 were Among children under two years of age, almost compared with respect to other drugs, significant all infections caused by penicillin-nonsuscepti- decreases were seen in the proportion of isolates ble strains were due to vaccine and vaccine-related that were nonsusceptible to trimethoprim–sulfa- serotypes, both before and after introduction of methoxazole, cefuroxime, meropenem, or clinda- the vaccine (Table 1). In this age group, a large mycin or to three or more drug classes, but there reduction in disease caused by vaccine serotypes 1458 n engl j med 354;14 www.nejm.org april 6, 2006 Downloaded from www.nejm.org on July 31, 2008 . Copyright © 2006 Massachusetts Medical Society. All rights reserved.
Descargar ahora